Journal of Microencapsulation Impact Factor & Information

Publisher: Informa Healthcare

Journal description

The Journal of Microencapsulation is a well-established journal devoted to the preparation, properties and uses of individually encapsulated small particles. Its scope extends beyond microcapsules to all other small particulate systems which involve preparative manipulation. These forms find a wide variety of medical, biological, industrial and research applications. The journal covers the chemistry of encapsulation materials; the physics of release through the capsule wall; the techniques of preparation; content and storage; and the many uses to which microcapsules are put. Also found in every issue of the journal is an extensive information and reference section comprising patent briefing and literature alerts listings.

Current impact factor: 1.59

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 1.585
2013 Impact Factor 1.878
2012 Impact Factor 1.571
2011 Impact Factor 1.553
2010 Impact Factor 1.515
2009 Impact Factor 1.89
2008 Impact Factor 1.314
2007 Impact Factor 1.168
2006 Impact Factor 0.805
2005 Impact Factor 1.37
2004 Impact Factor 1.492
2003 Impact Factor 0.915
2002 Impact Factor 1.024
2001 Impact Factor 0.966
2000 Impact Factor 1.076
1999 Impact Factor 0.991
1998 Impact Factor 0.841
1997 Impact Factor 0.775
1996 Impact Factor 0.514
1995 Impact Factor 0.783
1994 Impact Factor 0.442
1992 Impact Factor 0.43

Impact factor over time

Impact factor

Additional details

5-year impact 1.75
Cited half-life 9.30
Immediacy index 0.21
Eigenfactor 0.00
Article influence 0.36
Website Journal of Microencapsulation website
Other titles Journal of microencapsulation (Online)
ISSN 0265-2048
OCLC 41407365
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Informa Healthcare

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • On author's personal website or institution website
    • Publisher copyright and source must be acknowledged
    • Non-commercial
    • Must link to publisher version
    • Publisher's version/PDF cannot be used
    • NIH funded authors may post articles to PubMed Central for release 12 months after publication
    • Wellcome Trust authors may deposit in Europe PMC after 6 months
  • Classification

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Calcium alginate microbeads have been widely used in tissue engineering application, due to their excellent biocompatibility, biodegradability, enhanced mechanical strength and toughness. Bone powder containing abundant hydroxylapatite, type I collagen and growth factors such as BMP2 and BMP4, possesses good osteoinductive activity. Herein, a hybrid calcium alginate/bone powder microbead was therefore prepared. Afterwards, different seeding density of adipose-derived stem cells (ADSCs) in these hybrid microbeads was discussed systematically for further in vitro expansion. Optimised microbeads suitable for in vitro expansion and differentiation of ADSCs were prepared using the droplet method under overall considering suitable concentrations of calcium alginate and calcium chloride as well as the density of bone powder through an orthogonal experiment. The results showed that the concentration of sodium alginate had the most influence on inside mass transfer and mechanical strength of the hybrid microbeads, secondly the calcium chloride, then the density of bone powder. The hybrid microbeads could be optimally performed while the concentrations of sodium alginate and calcium chloride were 2.5% and 4.5%, as well as 5.0 mg/mL bone powder, respectively. Live/Dead assay showed that the expanded ADSCs differentiated well with an initial embedding density of 5 × 106 cells/mL.
    Journal of Microencapsulation 11/2015; 32(8):811-819. DOI:10.3109/02652048.2015.1094533
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nasal immunisation with nanoparticles has already shown promising results. In this study, nanoparticle composites carrying BSA for nasal vaccination prepared using electrostatic interaction process between polycation N-trimethyl chitosan chloride (TMC), chitosan glutamate (CG), chitosan chloride (CCl) and polyanion carboxymethyl pullulan (CMP). A mass ratio of 2:1 for TMC-CMP combination produced stable nanocarriers. For CCl-CMP and CG-CMP formulations needed a mass ratio of 3:1. Loading efficiency was >90% for all formulations. Nanoparticles size ranged from 207 to 603 nm. The surface charge of the complexes varied between +14 and +33 mV. SDS-PAGE integrity of the model antigen was also demonstrated. MTT studies showed that nanoparticle composites were less toxic to Calu-3 cells than the particles of cationic polymers alone. FITC-BSA loaded nanoparticles efficiently taken up by J774A.1 macrophages as confirmed by confocal microscopy highlighting the potential of these novel nanoparticulate carriers use for nasal vaccination.
    Journal of Microencapsulation 11/2015; 32(8):755-768. DOI:10.3109/02652048.2015.1073392

  • Journal of Microencapsulation 11/2015; 32(8):769-783. DOI:10.3109/02652048.2015.1073393

  • Journal of Microencapsulation 10/2015; 32(7):711-718. DOI:10.3109/02652048.2015.1073391
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To evaluate the protective effects of microencapsulation on Lactobacillus delbrueckii by random, parallel experimental design. Materials and methods: Lincomycin hydrochloride-induced intestinal malfunction mouse model was successfully established; then the L. delbrueckii microcapsule was given to the mouse. The clinical behaviour, number of intestinal flora, mucous IgA content in small intestine, IgG and IL-2 level in peripheral blood were monitored. The histological sections were also prepared. Results: The L. delbrueckii microcapsule could have more probiotic effects as indicated by higher bifidobacterium number in cecal contents. The sIgA content in microcapsule treated group was significantly higher than that in non-encapsulated L. delbrueckii treated group (p < 0.05). Intestine pathological damage of the L. delbrueckii microcapsule-treated group showed obvious restoration. Conclusion: The L. delbrueckii microcapsules could relieve the intestinal tissue pathological damage and play an important role in curing antibiotic-induced intestinal flora dysfunction.
    Journal of Microencapsulation 10/2015; 32(7):669-676. DOI:10.3109/02652048.2015.1057249
  • [Show abstract] [Hide abstract]
    ABSTRACT: SN-38 is a highly effective drug against many cancers. The development of an optimal delivery system for SN-38 is extremely challenging due to its low solubility and labile lactone ring. Herein, SN-38 encapsulated in poly(d,l-lactide-co-glycolide) nanoparticles (NPs) is introduced to enhance its solubility, stability and cellular uptake. SN-38-loaded NPs prepared by spontaneous emulsification solvent diffusion (SESD) method had an average diameter of 310 nm, a zeta potential of -9.69 mV and a loading efficiency of 71%. They were able to protect the active lactone ring of SN-38 against inactivation under physiological condition. A colorectal adenocarcinoma cell line (COLO-205) was used to assess the NPs effects on cytotoxicity and cellular uptake. Result showed a significant decreased cell proliferation and cell apoptosis. These results suggest that these SN-38-loaded NPs can be an effective delivery system for the treatment of colon cancer and potentially for other types of cancers.
    Journal of Microencapsulation 09/2015; DOI:10.3109/02652048.2015.1081416

  • Journal of Microencapsulation 08/2015; DOI:10.3109/02652048.2015.1073384
  • [Show abstract] [Hide abstract]
    ABSTRACT: Statins are drugs traditionally used to lower cholesterol levels in blood. At concentrations 100- to 500-fold higher than those needed for reaching cholesterol lowering activity, they have anti-tumour activity. This anti-tumour activity is based on statins pleiotropic effects derived from their ability to inhibit the mevalonate synthesis and include anti-proliferative, pro-apoptotic, anti-angiogenic, anti-inflammatory, anti-metastatic actions and modulatory effects on intra-tumour oxidative stress. Thus, in this review, we summarise the possible pleiotropic actions of statins involved in tumour growth inhibition. Since the administration of these high doses of statins is accompanied by severe side effects, targeted delivery of statins seems to be the appropriate strategy for efficient application of statins in oncology. Therefore, we also present an overview of the current status of targeted delivery systems for statins with possible utilisation in oncology.
    Journal of Microencapsulation 08/2015; 32(7). DOI:10.3109/02652048.2015.1073383
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of our study was to improve the bioavailability of acyclovir (ACV) by delivery of mucoadhesive nanoparticles (NPs) and controlled delivery of drug at its absorption window. Central composite design was used by which the effects of independent variables (gelatin and Pluronic F-68) on various responses such as particle size, polydispersity index, entrapment efficiency, loading efficiency, drug release and mucoadhesive strength were studied. The optimised formulation was evaluated for morphology, stability, pharmacokinetic and gastrointestinal tracking. The optimised NPs were found to be nearly spherical. Changes in characteristics of NPs were not significant after six months of accelerated stability studies. In vivo mucoadhesion study showed significant retention of mucoadhesive NPs in upper gastro-intestinal tract for more than 12 h. Pharmacokinetic study in rats revealed that mucoadhesive NPs could maintain relatively steady plasma concentration of ACV for more than 10 h. The AUC0–∞ and mean residence time of optimised formulation (7527.9 ng h/mL and 12.09 h) were significantly high than tablet dispersion (3841.13 ng h/mL and 7.97 h).
    Journal of Microencapsulation 08/2015; 32(6). DOI:10.3109/02652048.2015.1010457
  • [Show abstract] [Hide abstract]
    ABSTRACT: We prepared a magnetic chitosan-cis-aconitic anhydride-doxorubicin nanocomposite, denoted by MCS-CAA-DOX. Chitosan (CS) was linked to magnetic nanoparticles (Fe3O4) to decrease cytotoxicity of the composite and provided a large number of reactive sites for coupling of drug molecules. DOX was attached to the magnetic chitosan (MCS) via a pH-sensitive linker, cis-aconitic anhydride, which hydrolyses in the acidic lysosomal environment to allow pH-responsive release of DOX. The prepared nanocomposites were within 15 nm and had good superparamagnetic properties. The loading rate of DOX was up to 83%. It was found that nearly 88% DOX was released within 60 h at pH 5.0, compared with only 29% at pH 7.4.
    Journal of Microencapsulation 08/2015; 32(6). DOI:10.3109/02652048.2015.1065918
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Ciprofloxacin (CIP) was effective in treating bacterial keratitis. The purpose of this study was to prepare an effective prolonged-release of CIP by both temperature and pH-triggered in situ nanogels for the treatment of keratitis. Materials and methods: Poly(N-isopropylacrylamide-methacrylicacide-vinylpyrrolidone) [P (NIPAAm-MAA-VP)] nanoparticles was synthesised and used for preparation of CIP-loaded nanogels. Antimicrobial and in vivo animal studies of the CIP-loaded nanoformulation were performed. Results: Nanoformulation with a mean particle size between 10 and 50 nm and higher than 95% encapsulation efficiency was obtained. Ciprofloxacin released from the nanoparticles showed an enhanced antibacterial effect as determined by minimal inhibitory concentrations. In vivo studies demonstrated reasonable efficacy in severe keratitis using the developed nanoformulation. Conclusions: Nanoformulation had acceptable efficacy in treating bacterial keratitis in an animal model. Therefore, the developed system has the potential to be used in localised application for the treatment of keratitis.
    Journal of Microencapsulation 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this research was to evaluate the potential of water-in-oil-in-water (w/o/w) and solid-in-oil-in-water (s/o/w) emulsification techniques to prepare the altered collagen type II peptide AP268-270 (ACTP)-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres to make ACTP more convenient as an rheumatoid arthritis treatment. Microspheres produced by the s/o/w method had higher drug encapsulation efficiency (69.7–79.8%) than those prepared by the w/o/w method (21.8–39.3%). In vitro drug release was influenced by the microencapsulation technique, molecular weight, and composition of the polymer. After intramuscular injection of the optimal formulation to Lewis rats, the concentration of ACTP peptide in serum reached its maximum level on day 3 and then remained nearly stable for approximately 4 weeks. In a collagen-induced arthritis rat model, a single intramuscular injection of ACTP-loaded PLGA microspheres had comparable efficacy to the intravenous injection of ACTP peptide solution once every other day.
    Journal of Microencapsulation 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Effective clinical utilisation of non-steroidal anti-inflammatory drugs, such as diclofenac sodium (DS) is significantly limited by their ulcerogenic potential and poor bioavailability after oral administration. The objective of this work was to develop reconstitutable pediatric suspensions of DS-loaded microspheres prepared with an acrylic polymer (Eudragit RS) for improved pediatric delivery of DS. The microspheres were prepared by the water-in-oil-in-water or solid-in-oil-in-water emulsion techniques. Enviromental scanning electron microscopy observations clearly showed that microspheres have spherical shape. The drug entrapment efficiency of these microspheres was found 47.96 ± 0.79% to 88.57 ± 0.59% and their average particle sizes were 23.94–60.78 µm, which are within the desired range for the development of suspension formulation. The in vitro dissolution indicated prolonged sustained release of DS over 8 h. The results of preliminary characterisation studies of suspensions show that a liquid pharmaceutical preparation for oral administration capable of providing a sustained release of DS was successfully obtained.
    Journal of Microencapsulation 07/2015; 32(4). DOI:10.3109/02652048.2015.1017616